Large multicenter clinical trials have led to two recently approved drugs for patients with
idiopathic pulmonary fibrosis (IPF); yet, both of these therapies only slow disease …

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease of unknown etiology.
With a gradually increasing worldwide prevalence and a mortality rate exceeding that of …

Idiopathic pulmonary fibrosis (IPF) is an interstitial disease of unknown etiology
characterized by progressive pulmonary fibrosis. Pirfenidone and nintedanib are the only …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder
showcasing an interaction between genetic predisposition and environmental risks. This …

Idiopathic pulmonary fibrosis is an inexorably progressive lung disease with few available
treatments. New therapeutic options are needed. Stem cells have generated much …

Pulmonary fibrosis is a chronic progressive lung disease with few treatments. Human
mesenchymal stem cells (MSCs) have been shown to be beneficial in pulmonary fibrosis …

Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown
origin. Prognosis is poor, with limited treatment options available, and the median survival …

Background: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the
progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled …

OVERVIEW OF IPF AND EVIDENCE-BASED GUIDELINES of patients with a radiographic
and histopathologic pattern of usual interstitial pneumonia (UIP) and no other identifiable …

Gold nanoparticles (AuNPs) pose a great challenge in the development of nanotracers that
can self‐adaptively alter their properties in response to certain cellular environments for long …